Thyrotropin-releasing hormone (TRH, PyroGlu-His-Pro-NH 2 ) was the first brain peptide isolated from hypothalamus and is primarily responsible for the neuroendocrine regulation of thyrotropin secretion hormone (TSH) from the pituitary. 1, 2 Besides its function as the primary neurotrophic hormone, TRH and its analogues induce numerous behavioral effects 3, 4 such as the reduction of barbiturate narcosis or haloperidol-induced catalepsy, 5, 6 accelerateion of ACh turnover, 7 and improvement of memory and learning. 8 Therefore, peptides can be beneficial for treating motor neuron diseases, 9 spinal cord trauma, 10 Alzheimer's disease, 11 and West syndrome. 12 The therapeutic use of TRH in the treatment of age-related brain dysfunction is however limited primarily by its short half-life 13 and its inability to penetrate the Blood BrainBarrier (BBB). 14 In addition, TRH is rapidly metabolized in plasma by TRH-specific pyrogluamyl aminopeptidase and prolylendopeptidase. 15 Thus, strategies to deliver TRH to the brain must include not only protection of the peptide from the enzymes in plasma but the penetration of the BBB. The brain-enhanced delivery of TRH analogues was successfully achieved by our group 16 based on the sequential bioactivation of a brain-targeted construct with the molecular packaging method. In the case of previously reported Leu-TRH analogue, 17 the targeting construct constituted of DHT-ProPro-Gln-Leu-Pro-Gly-OCh, where the c-terminal Pro residue was extended with Gly residue in order to allow the formation of the prolinamide by PAM (peptidyl glycine α-amidating monooxygenase), resulted in significant reduction in the pentobarbital induced sleeping time in mice following iv administration. In the course of improving the stability of the TRH analogue or its precursors in the brain, we have identified that the prolinamide obtained from the Pro-Gly precursor by PAM was also susceptible to degradation that involved deamination by PPCE (a.k.a. TRH deaminase). 18 Since this process was a competitive side-reaction to the "designed-in" cleavage of the spacer-Gln peptide bond, we recently replaced the Pro-Gly c-terminal with pipecolic acid (Pip) and found that the replacement resulted in better in vivo stability. 19 In this study, we extended our approach to + m/z 347.
Nic-ProProGlnNva-OH (3). Fmoc-Nva-Wang resin was
Notes placed in a 200 mL reaction vessel, and the following steps were carried out: (1) deprotection of Fmoc group with piperidine/DMF (1 : 1, v/v, 3 min and then 7 min treatment), (2) washing, DMF (4 × 1 min), IPA (1 × 1 min), DMF (1 × 1 min), and DCM (4 × 1 min), (3) coupling with activated acid esters which were prepared from the reaction of the corresponding Fmoc-amino acids and nicotinic acid (3.0 equiv.), HOBt (3.0 equiv.), and DIC (3.0 equiv.) in 10 mL of DMA, and (4) washing, DMF (4 × 1 min), IPA (1 × 1 min), DMF (1 × 1 min), and DCM (4 × 1 min). The coupling time was for about 2 hour, and usually double coupling was applied. The completion of reaction was monitored by the Kaiser test. After coupling each residue to the resin step by step, the desired peptide was cleaved off by using TFA for 80 min. The TFA solution was concentrated and the residue was washed with ethyl ether three times to give a white precipitate. The precipitate was dried and recrystallized from DCM/hexane to give 350 mg of product (95% yield). HPLC showed the 99% of purity. Nic-ProProGlnNvaPip-OCh (5). To a solution of TFA salt of Nic-ProProGlnNva-OH (1.32 g, 2.00 mmol) and HOBt (264 mg, 2.00 mmol) in methylene chloride (15 mL) was added DCC (412 mg, 2.00 mmol) at 0 o C. After the mixture was stirred for 30 min at room temperature, H-Pip-O-Chloresterol (500 mg, 1.0 mmol) and DIEA (1.0 mL) was added. The resulting mixture was stirred for 40 hr at room temperature under nitrogen atmosphere, and then the precipitated DCU was filtered off. The filtrate was washed with methylene chloride (2 × 10 mL). The combined organic layer was washed with 5% citric acid solution (30 mL), saturated sodium bicarbonate solution (30 mL), water (30 mL) successively, and then dried over sodium sulfate. After the solvent was filtered and concentrated, the residue was purified on neutral alumna column chromatography to give a pure compound (450 mg, 44% 1,4-Dihydrotrigonellyl-ProProGlnNvaPip-OCh (7). To an ice-cold solution of Trig-ProProGlnNvaPip-OCh (400 mg, 0.320 mmol) in 60 mL of deariated water, sodium bicarbonate (580 mg, 7.00 mmol), sodium dithionate (2.10 g, 12.0 mmol) and 10 mL of ethyl acetate were added under nitrogen. The mixture was stirred at 0 o C for 5 min and another 100 mL of cooled ethyl acetate was added. The mixture was stirred for another 30 min at 0 o C, then for 50 min at room temperature. Ethyl acetate was separated and aqueous layer was extracted with 120 mL of ethyl acetate. The combined ethyl acetate extract was washed with 900 mL of 5% sodium bicarbonate solution, dried over sodium sulfate and distilled on a rotary evaporator to give the product (152 mg, 42% yield) as a yellowish solid. ]-TRH-CDS on the barbiturate-induced sleeping time in mice. Swiss Webster mice (body weight, 30 ± 3 g) were used. Freeze dried CDS-HPBCD (2-hydroxypropyl-β-cyclodextrin) complexes of TRH analogues were reconstituted by adding appropriate amount of HPBCD solution to obtain desired concentration of CDS in 30% HPBCD aqueous solution. Vehicle (3.0 µL/kg) only, or compounds at a dose of 10 µmol/kg (equimolar to 3.6 mg/ kg of TRH) were injected to the animals through tail. Ten minutes after iv injection of the compound, each animal received an intraperitoneal injection of sodium pentobarbital solution (30 mg/mL) at a dose of 60 mg/kg. The sleeping time was recorded as the time elapsed from the onset of loss of the righting reflex until the reflex was regained. Group of 6-7 animals were used for testing each compound. The students' t-test was used for the statistical analyses.
Results and Discussion
Synthesis. Since the stepwise elongation of the peptide chain from Fmoc-Pip-O-resin with activated ester of amino acid resulted in diketopiperazine formation, 20 [Nva
]-TRH-CDS was prepared by pentapeptide-single amino acid (5 + 1) segment-coupling approach. As shown in Scheme 1, two individual segments, NicProProGlnNva-OH and H-PipOCh, were prepared by the combined solid phase peptide synthesis (SPPS) and solution phase synthesis. The main fragment of the peptide chain, NicProProGlnNva-OH, was prepared by SPPS using an automated Fmoc chemistry protocol. The DIC mediated coupling was accelerated with HOBt. After completion of stepwise elongation, the crude peptide of NicProProGlnNva-OH (3) was cleaved off from the resin with TFA and recrystallized from DCM/hexane mixture.
The two fragments, NicProProGlnNva-OH (3) and H-Pip-O-Cholesterol (4), were assembled with DCC/HOBt system in DCM to give the crude product of 5, which was purified by column chromatography on neutral alumina with 5% MeOH/DCM eluent. Methylation of the pyridine ring (5) with dimethyl sulfate gave 6 in good yield. Finally, reduction of the trigonelloyl group with sodium dithionite gave the desired 1,4-dihydro product (7) .
Pharmacology. The antagonism of barbiturate-induced sleeping time in mice was used to assess the activation effect on mice cholinergic neurons of CNS delivered [Nva ]-TRH-CDS. In mice, ten minutes after iv administration of vehicle (30% hydroxypropyl-β-cyclodextrin, 1.5 mL/kg) or drug solution (10 µmole/kg) in the tail vein, 60 mg/kg of pentobarbital was ip injected. The sleeping time was recorded as the time elapsed from the onset of the righting reflex until the reflex was regained. As shown in Table 1 ]-TRH-CDS (50.8 ± 2.5 min and 49.8 ± 7.7 min respectively). These results indicated that the replacement of Leu residue with Nva didn't change activity, but the replacement of Pro-Gly residue with Pip residue significantly increases the activity. In conclusion, the present study demonstrated the successful delivery of [Nva 
